International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 417

PDF Downloaded: 226


Get Permission Jain, Das, Saxena, and Gupta: Evaluation of MMP-9 with atherogenic index and electrocardiogram as a predictor of cardiovascular risk factors in hypertensive patients


Introduction

Major modifiable risk factors for cardiovascular disease include hypertension, smoking, diabetes mellitus, and abnormal lipid levels. The strongest evidence for causation is connected with hypertension, which has a high exposure prevalence worldwide.1 37% of all strokes and 18% of myocardial infarction (MI) cases globally are attributed to hypertension.2 When either systolic, diastolic, or both are elevated, hypertension can be identified. Systolic blood pressure, which is higher when the heart is contracting (systole, and diastolic blood pressure, which is lower when the heart is relaxed (diastole).3

The majority of people (>95%) with high blood pressure have no known cause of their hypertension, which is sometimes referred to as primary or essential hypertension. The remaining 5% of patients had secondary causes found. The burden of hypertension disease is exacerbated by the presence of additional risk factors, such as dyslipidemia, which is more common in hypertensives and raises overall CV risk and results in atherosclerotic CV events.3

The extracellular matrix (ECM), which contains proteins like elastin and collagen fibers, gets rearranged in the vessels as a result of hypertension. In the extracellular matrix (ECM), the basement membrane, vascular smooth muscle cells migration, proliferation, contraction, and other processes, matrix metalloproteinases, which are proteolytic enzymes, can break down a variety of protein substrates.4

It has a specialized function in the development of blood vessels, tissue remodeling, and angiogenesis, all of which are triggered by a number of elements, including oxidative stress, inflammation, angiotensin II, and hemodynamic forces.4 Chronically high blood pressure values can trigger the activation of all these mechanisms. Several MMPs have been studied in humans, but MMP-2 and MMP-9, also known as gelatinase A and gelatinase B, respectively, are particularly important for vascular remodeling and are also in charge of breaking down denatured collagen, elastin, fibronectin, laminin, and type IV and V collagens, which are primarily found in the endothelial basement membrane of the vessel wall.5 Degradation of IV-type collagen, remodeling of the vasculature, angiogenesis, inflammation, and rupture of atherosclerotic plaque are all caused by MMP-2 and MMP-9.4 The degradation of arteries' elastic lamina and the development of aneurysms in both people and animals are linked to elevated MMP-9 activity. The development of hypertension may be accelerated by any change in MMP-9. Arteries become stiff due to chronic hypertension.6

MMPs may break down a wide range of ECM constituents, and it has been suggested that unbalanced MMP activity is a key factor in the remodeling of hypertensive vascular structures.6

Because increased vascular stiffness and elevated pulse pressure were observed in hypertensive MMP-9 knock-out mice, a recent study hypothesized that MMP-9 plays a positive role early in angiotensin-II-induced hypertension.6 Therefore, the primary goal of this study was to evaluate the growing cardiovascular risk in hypertension individuals.

Materials and Methods

Study design

Cross-sectional study. Standard normal range was used as control values for all parameters.

Study place

Department of Biochemistry, Rohilkhand Medical College & Hospital Bareilly (U.P).

Study duration

From September 2021 to March 2022.

Study subjects

A total of 162 patients with recently diagnosed mild-to-moderate hypertension with the age group of 18-44 years both male and female were compared with the 100 healthy individuals, who served as the study's controls visiting Medicine OPD, Rohilkhand Medical College & Hospital Bareilly.

Inclusion criteria

Patients with ≤ 130mmHg systolic blood pressure and ≤ 85mmHg diastolic blood pressure visit medicine OPD.

Exclusion criteria

  1. Persons having a previous history of diabetes mellitus, cardiovascular disease, and taking any medicine to affect reduced Blood pressure and diabetes mellites.

  2. Any renal, thyroid, and liver diseases are also excluded from the study.

  3. Pregnant women or having last 2-year history of pregnancy were also excluded from the study.

  4. Postmenopausal women and smokers & alcoholics were excluded from this study.

Study tools

  1. Anthropometric measurements- Blood pressure, Waist circumference.

  2. Laboratory investigations- lipid profile and MMP-9.

  3. Another parameter is electrocardiogram.

Methods of assay

  1. Blood pressure measurement: Blood pressure was measured by an auscultatory method using a standard cuff mercury sphygmomanometer on the left arm in a sitting position, after 5-10 min rest.7

  2. Waist circumferences: The WC was measured at the midway point between the lower rib margin and the crest of the ileum in a horizontal plane at a standing position (cm).8

  3. Estimation of fasting blood sugar: Fasting blood glucose level was determined by using the GOD-POD method (Glucose oxidase peroxidase method) by using of semi-autoanalyzer.9

  4. Estimation of serum lipid profile: The following parameters were estimated by using a fully autoanalyzer using kits.10

    1. Total cholesterol (TC), was estimated by using the CHOD-POD method.

    2. Triglycerides (TG) were estimated by the GPO-PAP method.

    3. High-Density lipoprotein-cholesterol (HDL-C) was estimated by CHOD-POD/Phosphotungstate method.

    4. Low-density lipoprotein-cholesterol (LDL-C) was estimated by using FRIEDEWALD’S equation.

    5. Atherogenic index was calculated by using the formula = log (TG/HDL-C).11

  5. Estimation of MMP-9 level – The serum MMP-9 level was measured by Enzyme-linked immunosorbent assay (ELISA) using the kit. (Cat. No E0936Hu, BioAssay Technology, Shanghai Korain Biotech, China).12

  6. Electrocardiography (ECG) measurements: Resting electrocardiography using a Sunfox Spandan 4.0 portable 12- lead ECG device was done. After explaining the procedure to the subject to allay anxiety, the upper clothing and all accessories (neckless, watches, rings) were removed. The electrocardiograph, which also consists of electrodes placed on the surface of the body, is used to perform the painless and straightforward ECG examination. The electrical currents are collected by the electrodes. The calibrations were 1mV=10 mm on the vertical line and an ECG speed of 25 mm/sec was used.13

This study was ethically approved (BIU/REG/Ph.D./321) by the institutional ethical committee of Rohilkhand Medical College. This research was conducted with Helsinki guidelines and informed consent was obtained from all participants.

Statistical analysis

All the parameters were expressed in Mean±SD. The independent t-test was applied among the various parameters for differentiating between the groups including the case and control groups. For testing qualitative data, the non-parametric chi-square test was used. The p-value <0.05 was considered statistically significant. All the statistical analysis was performed by means of IBM-SPSS (Statistical package for social sciences) version 23.0.

Results

A total of 162 hypertensive participants were selected for this study and compared with the 100 normal healthy controls. The demographic and clinical characteristics of both groups were summarized in Table 1.

The WC was increased and a p-value was <0.001, which is significant in the hypertensive group as compared to controls. Fasting blood glucose levels also increased in hypertensive subjects compared to the controls. A significant p-value (<0.001) was obtained. Lipid Profile, TC, TG, LDL, and VLDL were increased in hypertensive groups when compared to the controls which are significant, whereas HDL reduces in the hypertensive group as compared to controls. The enzymatic characterization MMP-9 level was higher in a hypertensive group than in control subjects. (Table 1). The mean of the P-R interval is higher in the hypertensive group when compared to the controls. As the same, the mean of the QRS and QT interval also increases and is positively significant in hypertensive patients as compared to the healthy controls. (Table 2). The subdivision of the case group into prehypertensive and hypertensive groups. We found 16 abnormal ECG and 61 abnormal Atherogenic Index in 86 prehypertensive groups while in 76 hypertensive groups we get 31 abnormal ECG and 57 abnormal atherogenic indexes. (Table 3)

Table 1

Difference among various parameters between case group and control group

Parameters

Hypertensive (162)

Control (100)

P value

WC

95.16±1.13

81.85±0.75

0.000

FBS

123.94±3.39

103.60±0.66

0.000

TC

201.37±2.421

173.15±2.25

0.041

TG

148.33±3.11

122.12±1.99

0.000

HDL

53.96±0.50

56.01±0.48

0.001

LDL

118.61±1.53

95.77±2.36

0.016

VLDL

29.88±0.62

24.32±0.39

0.000

TG/HDL

0.42±0.01

0.33±0.00

0.000

LDL/VLDL

2.89±0.04

1.82±0.05

0.001

MMP-9

121.65±1.74

50.51±0.49

0.001

[i] Data were expressed as Mean±SD. P value<0.05 is considered statistically significant.

Table 2

Comparison of quantitative ECG parameters between hypertensive and controls

Quantitative ECG Parameters

Hypertensive (162)

Control (100)

P value

Mean PR interval (sec)

158.40±4.90

144.31±2.31

0.010

Mean QRS interval (sec)

106.5±2.11

85.23±1.80

0.000

Mean QT interval (sec)

357.01±8.37

382.02±5.37

0.010

[i] Data were expressed as Mean±SD. P value<0.05 is considered statistically significant.

Table 3

ECG changes and Atherogenic index in different grades of hypertensive patients

Grading of Hypertension

Total 162

Electrocardiograph

Chi-square

p-value

Atherogenic Index

Chi-square

p-value

Normal

Abnormal

Normal

Abnormal

Prehypertensive

86

70

16

9.64

0.001

29

57

3.98

0.04

Hypertensive

76

45

31

15

61

Discussion

Hypertension is recognized globally as a significant risk factor for CVD, stroke, diabetes, and renal diseases. About 80% of hypertensive persons have comorbidities such as obesity, glucose intolerance, and abnormalities in lipid metabolism, among others.14 This study examined and evaluated the lipid abnormalities, atherogenic indexes, enzymatic abnormality, and ECG parameters among hypertensive patients as predictors of risk of developing cardiovascular diseases (CVDs). Diabetes one of the most common lifestyle disorders has been found to be associated with hypertensive patients. Various research has indicated this point very clearly since patients with hypertension often exhibit insulin resistance which might be the cause of developing diabetes in a later stage as compared to normotensive.15 This study is not an exception as their hypertensive patients were presented with increased concentration of fasting blood sugar compared to normal healthy adults which have supported by a Korean-based study when they investigated that subjects with hypertension were at higher risk of diabetes than normotensive subjects and further suggested early blood pressure management since active blood pressure control reduced incident diabetes.16

In this study, the mean value of serum TC, TG, LDL, and VLDL concentrations are significantly higher in hypertensive patients than in normotensive controls. While the mean HDL level was lower in the hypertensives compared to normotensives and was statistically significant. Our findings of increased levels of these parameters in hypertensive patients are similar to the findings of some other studies.11, 14, 17, 18

Electrocardiography is a non-invasive diagnostic modality that has a substantial clinical impact on investigating the severity of cardiovascular diseases. Eyoboglu M et al. concluded that fQRS may be a sign of increased blood pressure and may predict a higher fibrotic burden in patients with hypertension.19 In this study, there was an increased QRS interval in hypertensive patients compared to normotensive patients. PR prolongation could be considered a marker for cardiovascular degenerative aging caused by vascular inflammation and myocardial fibrosis when Papakonstantinou, et al concluded that PR interval is a significant predictor of new-onset AF in hypertensive patients.20 Similar to this there was a significantly increased PR interval in hypertensive patients compared to normal individuals.21 QT interval is a measure of the duration of ventricular depolarization and repolarization. In this study, there was a significantly increased QT interval observed in hypertensive patients, which has also been found in myocardial infarction, hypertrophic cardiomyopathy, hypertension, left ventricular hypertrophy, diabetes, chronic heart failure, mitral valve prolapse Studies have reported that prolonged QT interval has been reported with increased cardiovascular death among subjects with diabetes, hypertrophic cardiomyopathy, and cardiac failure.13, 22, 23 We observed that MMP-9 is present in significantly higher levels of hypertension than in normotensive controls which is consistent with previous studies.24, 25, 26 While according to Wiktor Kuliczkowski’s study there are no significant changes in mmp-9 concentrations in hypertensive.27 Elevation of MMP-9 is important because abnormal MMP levels can stimulate vascular inflammation, a potential contributor to the pathogenesis and progression of hypertension.28 Studies in the past have exposed the overproduction of MMP-9 plays a crucial role in the pathogenesis of coronary artery disease.29 In support of this study, Friese R et al also observed similar findings when they observed the higher concentration of MMP-9 in hypertensive patients compared to normotensive control.25 In this study there elevated concentration of MMP-9 was observed in hypertensive patients which might be responsible for the development of cardiovascular disease. In addition to this, studies have proven that deletion or inhibition of MMP-9 has proven beneficial in multiple animal models of cardiovascular disease.28

Conclusion

This study concludes that hypertension in the early stage is as harmful as in later stages, so proper blood pressure management requires as it is diagnosed. Although ECG findings cannot conclude an actual condition but can provide an actual direction in the general practice if taken into consideration. Abnormal findings of lipid profile with support of atherogenic index may define the presence of cardiovascular disease development in hypertensive patients. Increased concentration of MMP-9 in hypertensive may predict the presence of inflammation and fibrosis in cardiovascular disease. So, therapy related to reducing MMP-9 levels might be helpful to reduce the risk of cardiovascular disease. Further, studies with other parameters and an increased sample size might be conducted to explain a better picture of hypertension in the early stages.

Source of Funding

None.

Conflict of Interest

None.

References

1 

NRC Campbell PK Whelton M Orias RD Wainford FP Cappuccio N Ide 2022 World Hypertension League, Resolve to Save Lives and International Society of Hypertension dietary sodium (salt) global call to actionJ Hum Hypertens20221711010.1038/s41371-022-00690-0

2 

PM DaSilva MJ Lima PM Neves MED Macedo Prevalence of cardiovascular risk factors and other comorbidities in patients with hypertension in Portuguese primary health care populations: The PRECISE studyRev Port Cardiol (Engl Ed)201938642737

3 

Hypertension: managementPharm J20157110.1211/PJ.2015.20067719

4 

E Hopps RL Presti G Caimi Matrix Metalloproteases in Arterial Hypertension and their Trend after Antihypertensive TreatmentKidney Blood Press Res20174234757

5 

Yasmin CM Mceniery S Wallace Z Dakham P Pulsalkar K Maki-Petaja Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffnessArterioscler Thromb Vasc Biol2005252372

6 

MM Castro JE Tanus-Santos RF Gerlach Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertensionPharmacol Res201164656772

7 

GD James LM Gerber Measuring arterial blood pressure in humans: Auscultatory and automatic measurement techniques for human biological field studiesAm J Hum Biol201830110.1002/ajhb.23063

8 

K Krupp P Adsul ML Wilcox V Srinivas E Frank A Srinivas Prevalence and correlates of metabolic syndrome among rural women in Mysore, IndiaIndian Heart J202072658258

9 

A Ahmad RM Srikantiah C Yadav A Agarwal PA Manjrekar A Hegde Cord Blood Insulin Levels: It's Correlation with Gender, Birth Weight and Placental Weight in Term NewbornsIndian J Clin Biochem201631445862

10 

J Chahal S Gupta SPS Chawla H Grewal Comparative study on fasting and postprandial lipid profile in type 2 diabetes mellitusJ Family Med Prim Care2021103128893

11 

MA Olamoyegun R Oluyombo SO Asaolu Evaluation of dyslipidemia, lipid ratios, and atherogenic index as cardiovascular risk factors among semi-urban dwellers in NigeriaAnn Afr Med20161541949

12 

S Ahmad V Singh R J Sinha A Srivastava A Mandhani Role of MMP- 2, MMP-9 and VEGF as serum biomarker in early prognosis of renal cell carcinomaAfr J Urol20182425563

13 

AA Akintunde AT Oyedeji OB Familoni OE Ayodele OG Opadijo QT Interval prolongation and dispersion: Epidemiology and clinical correlates in subjects with newly diagnosed systemic hypertension in NigeriaJ Cardiovasc Dis Res2012342905

14 

KN Choudhury AK Mainuddin M Wahiduzzaman SM Islam Serum lipid profile and its association with hypertension in BangladeshVasc Health Risk Manag20141032732

15 

JR Petrie TJ Guzik RM Touyz Diabetes, Hypertension, and cardiovascular disease: Clinical Insights and Vascular MechanismsCan J Cardiol201834557584

16 

MJ Kim NK Lim SJ Choi HY Park Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology studyHypertens Res201538117839

17 

CU Osuji EG Omejua EI Onwubuya GI Ahaneku Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East NigeriaInt J Hypertens2012201271048610.1155/2012/710486

18 

AK Mahapatro S Chandrika R Chepuru A Study of Lipid Profile Abnormalities among Patients with Essential Hypertension Attending Tertiary Care CentreInt J Contemporary Med Res20227114

19 

M Eyuboglu Y Karabag S Karakoyun O Senarslan Z Tanriverdi B Akdeniz Usefulness of fragmented QRS in hypertensive patients in the absence of left ventricular hypertrophyJ Clin Hypertens (Greenwich)20171998615

20 

P Papakonstantinou I Andrikou D Konstantinidis K Tsioufis Pr Interval Duration As A Risk Factor For New-Onset Atrial Fibrillation In Patients With Arterial HypertensionJ Hypertens2022401e70

21 

GD Vaidean M Manczuk JW Magnani Atrial electrocardiography in obesity and hypertension: Clinical insights from the Polish-Norwegian Study (PONS)Obesity (Silver Spring)20162412260814

22 

GZ Sun Y Zhou N Ye SJ Wu YX Sun 1 Independent Influence of Blood Pressure on QTc Interval: Results from a General Chinese PopulationBiomed Res Int20192019165612310.1155/2019/1656123

23 

S Modak P Mehta J Patnaik Study on ECG Changes in Chronic hypertensive Patients in a Medical College Hospital of OdishaJ Med Sci Clin Res201645104737

24 

IK Onal B Altun ED Onal A Kirkpantur SG Oz C Turgan Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatmentEur J Intern Med200920436972

25 

RS Friese F Rao S Khandrika B Thomas MG Ziegler GW Schmid-Schönbein Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal diseaseClin Exp Hypertens200931752133

26 

FM Valente DO DeAndrade LN Cosenso-Martin CB Cesarino SM Guimarães VB Guimarães Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisisBMC Cardiovasc Disord202020113210.1186/s12872-020-01412-5

27 

W Kuliczkowski M Banaszkiewicz A Mysiak G Makaś I Bil-Lula Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary StudyCardiol Res Pract2019201969213110.1155/2019/6921315

28 

A Yabluchanskiy Y Ma RP Iyer ME Hall ML Lindsey Matrix metalloproteinase-9: Many shades of function in cardiovascular diseasePhysiology (Bethesda)2013286391403

29 

R Hassanzadeh-Makoui B Razi S Aslani D Imani SS Tabaee The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of coronary artery disease (CAD): a systematic review and meta-analysisBMC Cardiovasc Disord2020201232



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Original Article


Article page

286-290


Authors Details

Richa Jain, Biswajit Das, Shikha Saxena, Gaurav Gupta*


Article History

Received : 26-09-2022

Accepted : 14-10-2022


Article Metrics


View Article As

 


Downlaod Files